Today: 14 May 2026
Browse Category

Pharmaceuticals 11 January 2026 - 12 January 2026

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus

Arcutis Biotherapeutics shares fell 8.7% to $25.76 Monday after the company set a 2026 net product sales target of $455–$470 million for its ZORYVE franchise. The company reported $99.2 million in net product revenue last quarter and ended September with $191.4 million in cash. Arcutis plans to expand its sales team by 20% and expects key clinical trial data in early 2026. The stock hit a session low of $25.51.
12 January 2026
··
Merck (MRK) stock slides as JPMorgan conference tests deal buzz and vaccine risk

Merck (MRK) stock slides as JPMorgan conference tests deal buzz and vaccine risk

Merck shares fell 1.1% to $109.27 Monday amid speculation over a possible $28–32 billion acquisition of Revolution Medicines, though no deal has been finalized. The SPDR S&P Biotech ETF dropped 2.1%. Analysts estimate Revolution’s RAS inhibitor drugs could generate over $10 billion in sales by 2035. Merck also faces a potential $2 billion annual revenue hit after U.S. vaccine schedule changes affecting Gardasil and RotaTeq.
12 January 2026
··
Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead

Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead

Johnson & Johnson shares rose 2.3% to $209.03 after new data showed its drug Rybrevant, combined with chemotherapy, produced a 51% response rate in metastatic colorectal cancer. The results, from the OrigAMI-1 trial, included a 73% response rate in first-line patients. The company’s fourth-quarter earnings report is due Jan. 21. J&J recently struck a deal with the Trump administration to lower U.S. drug prices.
12 January 2026
···
AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy

AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy

AbbVie shares fell 0.6% to $218.81 after announcing a $650 million licensing deal with China’s RemeGen for the experimental cancer drug RC148. RemeGen could receive up to $4.95 billion in milestones and royalties. AbbVie also agreed to buy a device manufacturing plant in Tempe, Arizona, from West Pharmaceutical Services. The S&P health-care sector declined while the broader market rose.
12 January 2026
···
Why Recursion Pharmaceuticals (RXRX) stock is up today: a new JPM deck put cash runway back in focus

Why Recursion Pharmaceuticals (RXRX) stock is up today: a new JPM deck put cash runway back in focus

Recursion Pharmaceuticals shares rose 4.4% to $4.87 Monday after an updated investor presentation showed $755 million in cash at year-end 2025 and a projected runway through 2027. The company reported a 43% median reduction in polyp burden for its lead drug REC-4881 in a small trial, with mostly mild to moderate side effects. Recursion will present at the J.P. Morgan Healthcare Conference Tuesday.
12 January 2026
··
Revolution Medicines stock slips as Truist sticks to $99 target with Merck buyout talk in focus

Revolution Medicines stock slips as Truist sticks to $99 target with Merck buyout talk in focus

Revolution Medicines shares fell 1.8% to $116.51 in early Monday trading, retreating from last week’s highs after reports of ongoing Merck acquisition talks valuing the company at up to $32 billion. Truist maintained its Buy rating but kept its price target at $99, below the current price. Investors await the company’s presentation at the J.P. Morgan Healthcare Conference later Monday.
12 January 2026
··
Eli Lilly stock edges up as $1 billion Nvidia AI lab plan hits JPM spotlight

Eli Lilly stock edges up as $1 billion Nvidia AI lab plan hits JPM spotlight

Eli Lilly shares rose about 0.7% Monday after announcing a $1 billion, five-year AI drug discovery lab partnership with Nvidia. The Bay Area facility, using Nvidia’s Vera Rubin chips, will open in March with teams from both firms. Investors are watching for updates from CEO David Ricks at the J.P. Morgan Healthcare Conference on Tuesday and Lilly’s earnings call on Feb. 4.
12 January 2026
······
Teva stock jumps after $500 million Royalty Pharma deal as investors eye JPM update

Teva stock jumps after $500 million Royalty Pharma deal as investors eye JPM update

Teva shares rose about 4% to $33.29 after announcing a funding deal with Royalty Pharma worth up to $500 million for its experimental vitiligo drug. An SEC filing previewed Teva’s 2025 outlook, including projected revenue of $16.8–$17.0 billion and adjusted EBITDA of $4.8–$5.0 billion. Investors await more details at Tuesday’s J.P. Morgan Healthcare Conference.
12 January 2026
··
NovaBay Pharmaceuticals (NBY) stock slides premarket after 102% surge — dilution risk back on radar

NovaBay Pharmaceuticals (NBY) stock slides premarket after 102% surge — dilution risk back on radar

NovaBay Pharmaceuticals shares fell 10% to $17.21 in premarket trading Monday, following a 102.5% surge Friday on unusually heavy volume. Traders are watching for updates on warrants and share supply after the company disclosed possible new share issuances and a reverse split. NovaBay has not commented on the recent volatility. Fourth-quarter results are expected March 25.
12 January 2026
··
GSK stock in focus: JPMorgan healthcare agenda, merger chatter and key dates for investors

GSK stock in focus: JPMorgan healthcare agenda, merger chatter and key dates for investors

GSK shares slipped 0.03% to 1,885.5 pence in early London trading Monday, as investors awaited the company’s appearance at the J.P. Morgan Healthcare Conference in San Francisco on Tuesday. GSK’s ADRs closed up 0.3% in the U.S. at $50.39. Traders are watching for updates ahead of GSK’s full-year results due February 4.
12 January 2026
····
Novo Nordisk stock: Amazon starts selling Wegovy pill, putting next week in focus

Novo Nordisk stock: Amazon starts selling Wegovy pill, putting next week in focus

Novo Nordisk shares rose 3% in Copenhagen on Friday after Amazon Pharmacy began offering the Wegovy weight-loss pill with insurance and cash-pay options. U.S.-listed ADRs gained 2.6%. Amazon set insured prices as low as $25 per month, with cash prices starting at $149. Investors are watching CEO Mike Doustdar’s upcoming appearance at the J.P. Morgan Healthcare Conference.
11 January 2026
···
Merck (MRK) stock week ahead: $30 billion Revolution talks and JPMorgan catalysts to watch

Merck (MRK) stock week ahead: $30 billion Revolution talks and JPMorgan catalysts to watch

Merck shares fell 0.4% to $110.53 Friday as reports surfaced of talks to buy Revolution Medicines in a deal valued at $28 billion to $32 billion. Revolution shares jumped 10.7% on the speculation. The Wall Street Journal and Financial Times said the deal would be among the largest pre-commercial biotech acquisitions. Investors await updates at the JPMorgan Healthcare Conference on Monday.
11 January 2026
···
AstraZeneca stock: Nasdaq-100 exit date nears as index flows and JPM conference loom

AstraZeneca stock: Nasdaq-100 exit date nears as index flows and JPM conference loom

AstraZeneca will be removed from the Nasdaq-100 on Jan. 20, replaced by Walmart, Nasdaq said Friday. AstraZeneca shares rose 0.28% in London and 0.68% in New York after the announcement. Index funds are expected to adjust holdings near the effective date, potentially increasing trading volume. AstraZeneca management is set to speak at the JPMorgan Healthcare Conference starting Monday.
11 January 2026
····
Roche stock: $570 million MediLink cancer-drug deal puts Swiss shares back in focus

Roche stock: $570 million MediLink cancer-drug deal puts Swiss shares back in focus

Roche agreed to pay MediLink $570 million upfront and in near-term milestones for ex-China rights to experimental cancer drug YL201. Roche shares closed up 0.4% at 340.80 Swiss francs after the deal was announced. The Swiss SMI index hit a record high. Investors await Roche’s appearance at the JPM Healthcare Conference on Jan. 12 and its full-year earnings on Jan. 29.
11 January 2026
··
Johnson & Johnson stock in focus: Trump drug-price pact and fresh cancer data before Monday

Johnson & Johnson stock in focus: Trump drug-price pact and fresh cancer data before Monday

Johnson & Johnson shares fell 0.7% to $204.39 after announcing a deal with the Trump administration to cut U.S. drug prices in exchange for tariff exemptions. The company will offer some medicines at discounted rates via TrumpRx.gov but did not specify drugs or discount sizes. J&J also unveiled plans for two new U.S. manufacturing plants. Early trial data for its cancer drug amivantamab showed a 70% response rate in a first-line subgroup.
11 January 2026
··
Eli Lilly stock (LLY) slips into JPM Week as Amazon adds rival Wegovy pill — what to watch next

Eli Lilly stock (LLY) slips into JPM Week as Amazon adds rival Wegovy pill — what to watch next

Eli Lilly shares fell 1.99% to $1,063.56 Friday, trailing a record-setting S&P 500. Amazon Pharmacy began selling Novo Nordisk’s Wegovy pill for $149 a month, raising concerns about pricing pressure in obesity drugs. Lilly is set to address investors at the J.P. Morgan Healthcare Conference on Tuesday.
11 January 2026
······
OLMA stock jumps 10% into JPMorgan week — what to watch for Olema Pharmaceuticals

OLMA stock jumps 10% into JPMorgan week — what to watch for Olema Pharmaceuticals

Olema Pharmaceuticals shares jumped 9.8% to $28.08 Friday, with 2.5 million shares traded ahead of the CEO’s Jan. 13 presentation at the J.P. Morgan Healthcare Conference. Citi, UBS, and Piper Sandler issued bullish ratings and price targets up to $60, citing upcoming trial data and potential catalysts. Olema raised $218.5 million in November. The company has no approved products and is advancing two breast cancer drug candidates.
11 January 2026
·
NovaBay Pharmaceuticals stock jumps 102% — what to watch for NBY before Monday

NovaBay Pharmaceuticals stock jumps 102% — what to watch for NBY before Monday

NovaBay Pharmaceuticals shares jumped 102.5% to $19.16 Friday, with volume spiking to 10 million. The surge follows disclosures of pre-funded warrants and convertible preferred stock that could sharply increase the share count. David E. Lazar recently became CEO after leading a strategic investment. Traders await new filings and the U.S. CPI report on Jan. 13.
11 January 2026
··
1 … 15 16 17 18 19 … 40

Stock Market Today

  • LunR Royalties (TSXV:LUNR) Soars 84.6% in 2024 Despite No Revenue, Valuation Questions Arise
    May 14, 2026, 1:18 AM EDT. LunR Royalties (TSXV:LUNR) surged 84.6% year to date, reaching a CA$24 share price and a market cap near CA$1.68 billion. Despite this rally, the company posted no revenue and a net loss of CA$0.96 million. Its price-to-book ratio stands at an extreme 430.4x, vastly exceeding the Canadian metals and mining sector average of 3.2x. This valuation implies high investor expectations for future royalty income and project success, though the lack of current earnings and large valuation gap raise concerns about potential downside if exploration or timelines falter. Investors are urged to weigh these risks carefully before committing, considering the company's momentum balanced against its unproven profitability.

Latest articles

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 14.05.2026

14 May 2026
LIVEMarkets rolling coverageStarted: May 14, 2026, 12:00 AM EDTUpdated: May 14, 2026, 1:30 AM EDT LunR Royalties (TSXV:LUNR) Soars 84.6% in 2024 Despite No Revenue, Valuation Questions Arise May 14, 2026, 1:18 AM EDT. LunR Royalties (TSXV:LUNR) surged 84.6% year to date, reaching a CA$24 share price and a market cap near CA$1.68 billion. Despite this rally, the company posted no revenue and a net loss of CA$0.96 million. Its price-to-book ratio stands at an extreme 430.4x, vastly exceeding the Canadian metals and mining sector average of 3.2x. This valuation implies high investor expectations for future royalty income and project
Enovix Stock Drops After Q1 Beat as Smartphone Battery Tests Stay Unfinished

Enovix Stock Drops After Q1 Beat as Smartphone Battery Tests Stay Unfinished

14 May 2026
Enovix shares dropped 12.9% to $6.35 after hours Wednesday despite beating first-quarter revenue and adjusted-loss estimates. The decline followed news that smartphone battery qualification remains unfinished, with the company passing 72 of 75 customer tests. Revenue rose 49% to $7.6 million. Enovix cited progress in defense, industrial, and smart-eyewear sales.
Lightwave Logic Stock Jumps as AI-Photonics Bet Heads for a 2027 Production Test

Lightwave Logic Stock Jumps as AI-Photonics Bet Heads for a 2027 Production Test

14 May 2026
Lightwave Logic reported Q1 revenue up 27% to $29,000 and a net loss widening to $6.3 million. Shares rose 14% after the company said it is negotiating a supply and licensing deal for high-volume production in 2027. Four Fortune 500 customers are now in Stage 3 prototyping. Cash and equivalents totaled about $100 million as of May 11.
Go toTop